<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04810208</url>
  </required_header>
  <id_info>
    <org_study_id>NZ-DTX-001</org_study_id>
    <nct_id>NCT04810208</nct_id>
  </id_info>
  <brief_title>Intratumoural Injection of a Novel NanoZolid®-Docetaxel Depot Formulation in Patients With Advanced Solid Tumours</brief_title>
  <official_title>A Phase Ia/Ib, First-in-human, Open Label, Multicentre, Dose-escalation and Dose-expansion Study of a Novel NanoZolid®-Docetaxel Depot Formulation (NZ-DTX Depot) Given as an Intra-tumoural Injection in Patients With Advanced Solid Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lidds AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lidds AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicentre, open-label, first in man, study of a novel NanoZolid®-docetaxel depot&#xD;
      formulation (NZ-DTX Depot) given as an intra-tumoural injection in patients with advanced&#xD;
      solid tumours. The study includes a dose escalation part and a dose expansion part.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2019</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of NZ-DTX Depot given as an intra-tumoural injection in solid, palpable, cutaneous or subcutaneous tumour lesions.</measure>
    <time_frame>5 weeks</time_frame>
    <description>The MTD will be determined by incidence of DLTs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The recommended Phase 2 dose (RP2D) of NZ-DTX Depot given as an intra-tumoural injection in a solid, palpable cutaneous or subcutaneous tumour lesion.</measure>
    <time_frame>5 weeks</time_frame>
    <description>The RP2D will be determined by frequency and severity of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of treatment-emergent adverse events [safety and tolerability] following an intratumoural injection of NZ-DTX Depot</measure>
    <time_frame>5 weeks</time_frame>
    <description>Frequency and severity of treatment-emergent adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of docetaxel, following an intratumoural injection of NZ-DTX Depot</measure>
    <time_frame>5 weeks</time_frame>
    <description>Plasma concentration of docetaxel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumour effect following an intratumoural injection of NZ-DTX Depot</measure>
    <time_frame>5 weeks</time_frame>
    <description>Tumour response by RECIST</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Presence of immune biomarkers in plasma, following an intratumoural injection of NZ-DTX Depot</measure>
    <time_frame>9 weeks</time_frame>
    <description>Analysis of cytokines in plasma</description>
  </other_outcome>
  <other_outcome>
    <measure>Presence of immune biomarkers in tissue, following an intratumoural injection of NZ-DTX Depot</measure>
    <time_frame>9 weeks</time_frame>
    <description>Immunohistochemistry analysis [PD-L1] in tissue</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>NZ-DTX Depot</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel in NanoZolid formulation, for intratumoural injection</description>
    <arm_group_label>NZ-DTX Depot</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed written informed consent granted before undertaking any study-specific&#xD;
             procedures;&#xD;
&#xD;
          2. Male or female patient ≥18 years of age on the day of consenting to the study;&#xD;
&#xD;
          3. Histologically or cytologically confirmed diagnosis of solid cancer;&#xD;
&#xD;
          4. At least 1 advanced solid, palpable, cutaneous or subcutaneous tumour lesion with&#xD;
             following characteristics:&#xD;
&#xD;
               -  a cutaneous lesion with of thickness ≥4 mm and diameter ≥25 mm at the longest&#xD;
                  axis, or&#xD;
&#xD;
               -  a subcutaneous lesion of diameter ≥20 mm at the longest and the shortest axis;&#xD;
&#xD;
          5. Eastern Co-operative Oncology Group (ECOG) performance status (PS) 0-2;&#xD;
&#xD;
          6. Patient from one the following categories:&#xD;
&#xD;
               -  Patient for whom no standard therapy exists, or standard therapy is&#xD;
                  contraindicated, or&#xD;
&#xD;
               -  Patient who is scheduled for other anti-cancer treatment (e.g. radiotherapy,&#xD;
                  immunological treatment, surgery) which will start after completion of at least&#xD;
                  one treatment cycle of NZ-DTX, i.e after the end-of-study (EOS) visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known hypersensitivity to any of the excipients in the NZ-DTX Depot formulation&#xD;
             (docetaxel, calcium sulphate, sodium carboxymethylcellulose);&#xD;
&#xD;
          2. Life expectancy &lt;3 months;&#xD;
&#xD;
          3. Bleeding deficiencies or ongoing anticoagulant therapy that would put the patient at&#xD;
             increased risk of clinically significant bleeding, in the judgement of the&#xD;
             Investigator. If the patient has an international normalised ratio (INR) below 1.2 the&#xD;
             Investigator may judge if interruption of anticoagulant therapy is warranted;&#xD;
&#xD;
          4. Any of the following abnormal laboratory values at screening;&#xD;
&#xD;
               -  Bone marrow function:&#xD;
&#xD;
                    -  Absolute neutrophil count (ANC) &lt;1.5 x 109/l;&#xD;
&#xD;
                    -  Platelet count &lt;100 x 109/l;&#xD;
&#xD;
                    -  Haemoglobin &lt;9.0 mg/dl.&#xD;
&#xD;
               -  Coagulation:&#xD;
&#xD;
                  - International Normalized Ratio (INR) &gt;1.2.&#xD;
&#xD;
               -  Hepatic, renal, and biochemistry parameters:&#xD;
&#xD;
                    -  Aspartate transaminase (AST) or alanine transaminase (ALT) &gt;2.5 x upper&#xD;
                       limit of normal (ULN) (&gt;5 x ULN if liver metastases present)*;&#xD;
&#xD;
                    -  Alkaline phosphatase (ALP) &gt;2.5 x ULN;&#xD;
&#xD;
                    -  Total bilirubin &gt;1.5 x ULN;&#xD;
&#xD;
                    -  Estimated glomerular filtration rate (eGFR) &lt;40 ml/min/1.73 m² using the&#xD;
                       Modified Cockcroft &amp; Gault formula.&#xD;
&#xD;
                         -  For patients with liver impairment who have serum transaminase levels&#xD;
                            (ALT and/or AST) greater than 1.5 times x ULN - the doses will be&#xD;
                            restricted to max. 75mg/m2. In the event this is not possible the&#xD;
                            patient will not be included.&#xD;
&#xD;
          5. Severe fluid retention, e.g. pulmonary oedema, pleural effusion, pericardial effusion&#xD;
             or ascites;&#xD;
&#xD;
          6. Clinically significant heart disease (i.e. heart failure or myocardial infarction&#xD;
             within 6 months of screening, instable angina pectoris);&#xD;
&#xD;
          7. History of thromboembolic or cerebrovascular events within 6 months of screening;&#xD;
&#xD;
          8. Major surgery within 2 weeks of screening, or patient not recovered from major&#xD;
             surgery;&#xD;
&#xD;
          9. Known untreated or uncontrolled acute infection, including urinary tract infection,&#xD;
             within 7 days of screening;&#xD;
&#xD;
         10. Not recovered from Grade 2 or higher adverse events (AEs) due to previous treatments,&#xD;
             excepting alopecia;&#xD;
&#xD;
         11. Concurrent participation in another investigational study;&#xD;
&#xD;
         12. Last investigational drug administration in a prior investigational study within 14&#xD;
             days of study treatment initiation or &lt;5 times the half-life of the investigational&#xD;
             drug, whichever is longer;&#xD;
&#xD;
         13. Last administration of other anti-neoplastic drug within 14 days of study treatment&#xD;
             initiation;&#xD;
&#xD;
         14. Radiotherapy of lesion to be injected within 4 weeks of first treatment with NZ-DTX&#xD;
             Depot, or irradiated lesion to be injected without signs of disease progression since&#xD;
             irradiation;&#xD;
&#xD;
         15. For men and women of childbearing potential: Unwillingness to follow contraception&#xD;
             requirements;&#xD;
&#xD;
         16. Female patients with planned or current pregnancy and/or currently breastfeeding;&#xD;
&#xD;
         17. Any other severe, acute or chronical medical or psychiatric condition or laboratory&#xD;
             abnormality that, in the judgement of the Investigator, would make the patient&#xD;
             inappropriate for study participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charlotta Gauffin, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Lidds AB</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charlotta Gauffin, PhD</last_name>
    <phone>+46763159365</phone>
    <email>charlotta.gauffin@liddspharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dorte Nielsen, M.D. Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lithuanian University of Health Sciences</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Laura Kairevice, M.D. Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vincas Urbonas, M.D. Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jeffrey Yachnin, M.D. Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Lithuania</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 18, 2021</study_first_submitted>
  <study_first_submitted_qc>March 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2021</study_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

